GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (OTCPK:RAONF) » Definitions » Cyclically Adjusted PS Ratio

Race Oncology (Race Oncology) Cyclically Adjusted PS Ratio : (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Race Oncology Cyclically Adjusted PS Ratio?

Race Oncology does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Race Oncology Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Race Oncology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Cyclically Adjusted PS Ratio Chart

Race Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial - - - - -

Race Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Race Oncology's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Race Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Race Oncology's Cyclically Adjusted PS Ratio falls into.



Race Oncology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Race Oncology does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Race Oncology  (OTCPK:RAONF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Race Oncology Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Race Oncology's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology (Race Oncology) Business Description

Traded in Other Exchanges
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.

Race Oncology (Race Oncology) Headlines